ALCAM and BCAM: Two New Breast Cancer Biomarkers

描述（由申请人提供）：乳腺癌是影响全球数百万妇女的主要健康问题。与乳腺癌作斗争的方法之一是早期诊断和有效治疗。对于那些疾病在晚期被诊断的患者，准确监测以评估治疗反应是重要的。不幸的是，到目前为止，由于缺乏高质量的血液生物标志物，还没有有效的方法来诊断乳腺癌或进行监测。在这项拨款申请中，我们的目标是验证两个新发现的候选乳腺癌生物标志物。我们将使用治疗前采集的样本[用于诊断应用]和治疗期间采集的多年样本[用于监测治疗反应]。我们的初步数据表明，这些新发现的生物标志物的表现优于经典和商业上可用的乳腺癌生物标志物CA15.3。如果我们的结果是有希望的，他们可能会导致乳腺癌的早期诊断和更好地监测那些谁是化疗或其他方案治疗的患者的新方法。我们的积极数据可能会改善乳腺癌的诊断和监测方式，最终目标是延长患者的生存期并提高生活质量。 公共卫生相关性：我们最近发现了两种新的乳腺癌生物标志物。我们的初步数据是非常有希望的，关于使用这些生物标志物早期诊断乳腺癌和监测患者谁有先进的疾病和治疗的各种方式。如果我们成功的话，这两种新的生物标志物可能在改善早期乳腺癌的诊断和优化已经患有这种疾病的患者的治疗方案方面发挥重要作用。

DESCRIPTION (provided by applicant): Breast cancer is a major health problem affecting millions of women worldwide. One of the ways to combat breast cancer is by early diagnosis and administration of effective therapy. For those patients whose disease is diagnosed at a late stage, accurate monitoring for assessing response to treatment is important. Unfortunately, until now, there is no effective means for diagnosing breast cancer or for monitoring, due to the lack of high-quality blood-based biomarkers. In this grant application, our aim is to validate two newly discovered candidate breast cancer biomarkers. We will use samples that have been collected before treatment [for the diagnostic application] and samples that have been collected during therapy, over many years [for the application of monitoring response to therapy]. Our preliminary data indicate that these newly discovered biomarkers perform better than the classical and commercially available breast cancer biomarker, CA15.3. If our results are promising, they may lead to new ways for early diagnosis of breast cancer and for better monitoring of those patients who are treated with chemotherapy or other regimens. Our positive data may improve the way breast cancer is diagnosed and monitored, with the ultimate goal of extending patient survival and improve quality of life. PUBLIC HEALTH RELEVANCE: We have recently discovered two new breast cancer biomarkers. Our preliminary data are highly promising, regarding use of these biomarkers for early diagnosis of breast cancer and for monitoring patients who have advanced disease and are treated with various modalities. If we are successful, these two new novel biomarkers may play a major role in improving the diagnosis of early breast cancer and in optimizing therapeutic regimens of patients who already have the disease.